PF-07263689 / Pfizer - LARVOL DELTA

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=13 | Terminated | Sponsor: Pfizer | N=10 ➔ 13 | Active, not recruiting ➔ Terminated; The study was terminated by the Sponsor due to business decision and not due to any safety concerns with PF-07263689. There are no changes to the risk-benefit for participants who have received PF-07263689 in the study.

Combination therapy • Enrollment change • Metastases • Trial termination • Bladder Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer • IL2

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=120 ➔ 10 | Trial completion date: Apr 2025 ➔ Dec 2022 | Trial primary completion date: Apr 2025 ➔ Dec 2022

Combination therapy • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Bladder Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer • IL2

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Pfizer | Trial completion date: Aug 2024 ➔ Mar 2025 | Trial primary completion date: Aug 2024 ➔ Mar 2025

Combination therapy • Trial completion date • Trial primary completion date • Bladder Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer • IL2

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1; N=120; Recruiting; Sponsor: Pfizer; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Bladder Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer • IL2

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1; N=120; Not yet recruiting; Sponsor: Pfizer

Clinical • Combination therapy • New P1 trial • Bladder Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer • IL2